Basic information about the included RCTs.

Numerous lipid-lowering medications are commonly used in clinical settings; however, their impact on vascular endothelial function remains unclear. This study employed techniques like flow-mediated dilation (FMD) to demonstrate the relative effects of lipid-lowering medications on vascular function. PubMed, Embase, and World of Science were searched from January 1, 2011 to October 1, 2024, and the language was limited to English. Randomized controlled trials (RCTs) have assessed the impact of lipid-lowering medications versus placebos on FMD in individuals. The outcomes included FMD, pulse wave velocity (PWV), low-density lipoprotein cholesterol (LDL-C), peak O2 consumption (VO2), and intimal media thickness (IMT). We computed standardized mean differences and 95% confidence intervals (CIs). P 2 = 43%, 14 trials, 726 participants), LDL-C (−1.54 [95% CI: −1.78, −1.30], P 2 = 25%, 7 trials, 350 participants) and PWV (−0.35 [95% CI: −0.57, −0.02], P = 0.04, I2 = 0.0%, 4 trials, 206 participants). Lipid-lowering drugs positively affect endothelial function, while lowering blood lipids and statins are the most effective.